Welcome to our dedicated page for RAPT Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RAPT Therapeutics, Inc. filings document the regulatory record of a clinical-stage immunology biopharmaceutical company and its transition from a Nasdaq-listed issuer to a wholly owned subsidiary of GlaxoSmithKline LLC. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentation materials, material agreements, capital-structure matters, and shareholder-related transaction disclosures.
Later filings include a Form 25 for removal of RAPT common stock from Nasdaq listing and registration, and a Form 15 covering termination of registration or suspension of reporting duties for its common stock. These documents record the completed merger, the surviving-company structure, the delisting process, and Exchange Act reporting-status changes.
RAPT Therapeutics director Ashley L. Dombkowski received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a grant price of $0. These RSUs were issued under RAPT’s Amended & Restated Non-Employee Director Compensation Policy.
The 4,956 RSUs fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of RAPT common stock upon vesting, and all 4,956 shares are reported as directly owned following this grant.
RAPT Therapeutics received an all-cash tender offer at $58.00 per share from Redrose Acquisition Co., a wholly owned GSK subsidiary, to acquire all outstanding common stock via a tender offer followed by a short-form merger under Delaware law. The board unanimously determined the offer and merger consideration are fair and in the best interests of stockholders and recommends that holders tender their shares. As of January 30, 2026, RAPT had 30,922,702 shares outstanding, plus additional shares issuable under options, RSUs and pre-funded warrants, which will be cashed out or converted into cash-based awards based on the $58 price. Executive officers and directors will receive the same per-share price as other investors, and change-in-control arrangements and equity acceleration produce substantial "golden parachute" payouts, including significant cash and equity value for the CEO and other named executives. The merger agreement also provides post-closing indemnification and D&O insurance protections and commits GSK to maintain specified compensation and benefit levels for continuing employees for one year after closing.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has launched an all-cash tender offer to acquire RAPT Therapeutics, Inc.. The offer is for $58.00 per share for each share of RAPT common stock, payable in cash without interest and subject to withholding taxes.
The offer covers all outstanding RAPT common shares and is made pursuant to an Agreement and Plan of Merger dated January 19, 2026. RAPT has advised that 30,922,702 shares of common stock were issued and outstanding as of the close of business on January 28, 2026.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has filed pre-commencement materials for a planned cash tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. common stock under an Agreement and Plan of Merger dated January 19, 2026.
The tender offer has not yet started. Once it begins, GSK and its affiliates will file a full tender offer statement on Schedule TO, and RAPT will file a Schedule 14D-9 explaining the board’s recommendation. Stockholders are urged in the communication to read these future documents carefully when available, as they will contain detailed terms of the offer, conditions to closing and other important information, alongside extensive forward-looking statement and risk-factor disclosures about the proposed acquisition and related clinical and regulatory expectations.
RAPT Therapeutics, Inc. is the target of a planned acquisition by GSK plc, which intends to launch a cash tender offer for all issued and outstanding shares of RAPT common stock. The transaction will be carried out through GSK’s subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co. under an Agreement and Plan of Merger dated January 19, 2026.
The filing is a pre-commencement communication, meaning the tender offer has not yet begun. Once it starts, GSK will file a detailed Schedule TO and RAPT will file a Schedule 14D‑9, providing terms of the offer and the board’s recommendation. The document also includes extensive forward‑looking statement disclosures, highlighting risks such as timing of the offer, satisfaction of closing conditions, required regulatory approvals, potential termination of the merger agreement and possible business disruptions if the deal does not close.
RAPT Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger with GlaxoSmithKline LLC under which a GSK subsidiary will launch a cash tender offer to acquire all outstanding RAPT common shares at $58.00 per share, without interest and subject to withholding taxes. Completion of the offer is conditioned on a majority of RAPT shares being tendered and on required antitrust clearances under the HSR Act, among other customary conditions. After the offer closes, the buyer’s subsidiary will merge into RAPT, which will become a wholly owned GSK subsidiary, and remaining shares will receive the same cash price. The agreement includes a $78.4 million termination fee payable by RAPT in certain circumstances and a $100.8 million reverse termination fee payable by GSK if specified regulatory-related conditions are not met by the contractual end date.
RAPT Therapeutics, Inc. filed a current report to let investors know that the company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is providing its conference presentation as Exhibit 99.1, described as a corporate presentation, and making it available for transparency under Regulation FD, which governs fair disclosure of information to investors. The report also clarifies that the presentation and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings unless specifically referenced.
RAPT Therapeutics (RAPT) filed its Q3 2025 10-Q, reporting a net loss of $17.6 million for the quarter and $52.4 million year-to-date as the company advances its immunology pipeline. Operating expenses were $19.4 million in Q3, led by research and development of $12.0 million and general and administrative of $7.3 million. Other income contributed $1.8 million in the quarter.
Liquidity remains solid with $157.3 million in cash, cash equivalents and marketable securities as of September 30, 2025, and operating cash outflows of $76.1 million for the nine months. After quarter end, RAPT completed an underwritten offering of 8,333,334 shares at $30.00 per share for net proceeds of approximately $234.4 million, bolstering its cash resources. Shares outstanding were 27,710,871 as of November 3, 2025.
The company initiated the prestIgE Phase 2b trial of ozureprubart in food allergy and announced positive topline data from Jeyou’s Phase 2 ozureprubart trial in chronic spontaneous urticaria, where dosing every 8 or 12 weeks showed comparable efficacy to omalizumab dosed every 4 weeks. RAPT also effected a 1‑for‑8 reverse stock split in June 2025.
RAPT Therapeutics filed an 8‑K stating it furnished a press release announcing financial results for the quarter and nine months ended September 30, 2025. The release is included as Exhibit 99.1.
The company states the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other SEC filings.
RAPT Therapeutics announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters will purchase shares at $28.20 each, and have a 30-day option to buy up to 1,250,000 additional shares.
The company estimates net proceeds of $234.4 million, or $269.7 million if the option is fully exercised. RAPT states that these proceeds, together with existing cash, cash equivalents and marketable securities, are expected to fund operations into 2028. Closing is expected on October 23, 2025, subject to customary conditions. The offering is being made under an effective Form S-3 and prospectus supplement.